Key Takeaways
Achieve Life Sciences (Nasdaq: ACHV) shares fell 9.83% Tuesday despite the company presenting positive long-term safety data for its smoking cessation drug, cytisinicline, from a 475-participant study.
"The ORCA-OL data represent an important milestone in our regulatory pathway," Andrew D. Goldberg, MD, Chief Executive Officer of Achieve, said. "With our complete clinical evidence package now in hand, we are positioned to advance cytisinicline toward potential approval."
The data from the 52-week ORCA-OL trial, presented at the American Thoracic Society 2026 Annual Meeting, showed a low incidence of nausea at 2.5 percent, a common side effect with other smoking cessation therapies. While 66.3 percent of participants experienced adverse events, 94.8 percent of those were mild to moderate, and only 5.7 percent of participants discontinued the trial due to treatment-related adverse events. No new safety signals were identified.
The stock's decline to $4.77 contrasts with recent gains following financing and leadership news, suggesting the drop may be tied to broader biotech sector weakness rather than the data itself. The results complete the evidence package for the company's New Drug Application (NDA) with the U.S. Food and Drug Administration, which has a target action date of June 20, 2026. The positive safety profile, particularly the low nausea rate, positions cytisinicline as a potentially strong competitor to existing treatments like varenicline. Investors are now focused on the upcoming PDUFA date as the next major event for the company.
This article is for informational purposes only and does not constitute investment advice.
